HLS Therapeutics (HLS) Competitors

HLS Therapeutics (TSE:HLS) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Which has preferable valuation and earnings, HLS or GUD?

HLS Therapeutics has higher earnings, but lower revenue than Knight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.42M	3.14	-C$15.53M	-C$0.48	-11.77
Knight Therapeutics	C$384.56M	1.57	-C$30.73M	N/A	N/A

Is HLS or GUD more profitable?

Knight Therapeutics has a net margin of -8.81% compared to HLS Therapeutics' net margin of -38.70%. Knight Therapeutics' return on equity of -4.04% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-38.70%	-25.27%	-2.89%
Knight Therapeutics	-8.81%	-4.04%	0.51%

Which has more volatility and risk, HLS or GUD?

HLS Therapeutics has a beta of 0.650839, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.219245, indicating that its share price is 78% less volatile than the S&P 500.

Do analysts prefer HLS or GUD?

HLS Therapeutics currently has a consensus target price of C$5.00, indicating a potential downside of 11.50%. Knight Therapeutics has a consensus target price of C$7.15, indicating a potential upside of 17.79%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than HLS Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do insiders & institutionals hold more shares of HLS or GUD?

0.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Knight Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media prefer HLS or GUD?

In the previous week, HLS Therapeutics had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for HLS Therapeutics and 1 mentions for Knight Therapeutics. HLS Therapeutics' average media sentiment score of 0.63 beat Knight Therapeutics' score of 0.59 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HLS Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Knight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Knight Therapeutics beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.